stockrow
Saturday 7 November 2026
Export NXTC’s income statement to Excel — free account
NextCure, Inc.
NXTC Healthcare Biotechnology
- EPS
- +75.2%
- Free cash flow
- +57.2%
Quarter to June 2026, against a year earlier
5.30
0.18
+3.52%
Follow NXTC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 6 | 22 | — | — | — | — | — | 27 | +252.6% | — | — | 6 | — | |
| Gross margin, % | — | 0.00 | 0.00 | 100.00 | 100.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | (15) | (23) | (34) | (37) | (69) | (75) | (63) | (56) | (56) | (43) | +17.4% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | (531.54) | (163.57) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | (15) | (23) | (34) | (37) | (69) | (75) | (63) | (56) | (56) | (43) | +17.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 4.85 | 9.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (135.65) | (199.78) | (25.81) | (15.97) | (30.13) | (32.29) | (27.01) | (23.89) | (19.65) | (10.26) | (21.5%) | ||||||
| Cash flow | — | (109.77) | 70.04 | (27.25) | (19.60) | (24.90) | (23.32) | (22.85) | (17.51) | (17.45) | (6.97) | (20.5%) | ||||||
| Capex | — | (75.89) | (26.84) | (2.58) | (3.11) | (1.03) | (0.92) | (0.35) | (0.20) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | (185.67) | 43.20 | (29.83) | (22.71) | (25.93) | (24.23) | (23.20) | (17.71) | (17.45) | (6.97) | (25.6%) | ||||||
| Book value | — | 136.74 | 1,010.33 | 245.90 | 128.07 | 101.45 | 72.49 | 49.34 | 28.09 | 12.29 | 2.29 | (26.0%) | ||||||
| Shares, m | — | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | +49.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | 139.25 | 10.96 | — | — | — | — | — | 1.03 | 75.1 | ||||||
| P/B | — | — | — | 2.75 | 1.02 | — | — | — | — | — | 2.32 | 1.9 | ||||||
| EV/Sales | — | — | — | 87.05 | 0.67 | — | — | — | — | — | 0.39 | 43.9 | ||||||
| EV/FCF | — | — | — | (14.17) | (0.35) | — | — | — | — | — | (0.29) | (7.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (13) | 8 | (36) | (45) | (57) | (54) | (53) | (41) | (50) | (37) | +18.8% | |||||
| Capex | — | (9) | (3) | (3) | (7) | (2) | (2) | (1) | 0 | — | 0 | (34.0%) | ||||||
| Free cash flow | — | (21) | 5 | (39) | (52) | (60) | (56) | (54) | (41) | (50) | (37) | +11.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 6 | 125 | 325 | 278 | 221 | 155 | 106 | 62 | 33 | 16 | +23.1% | |||||
| Net debt | — | (8) | (135) | (331) | (282) | (220) | (160) | (108) | (69) | (42) | (20) | +22.2% | ||||||
| Shareholders’ equity | — | 16 | 115 | 321 | 294 | 233 | 168 | 114 | 65 | 35 | 12 | +10.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (18.52) | (27.29) | (13.39) | (11.04) | (25.28) | (35.04) | (40.18) | (53.28) | (85.23) | (121.60) | (66.7) pt | |||||
| ROIC | — | (135.71) | 0.00 | 0.00 | (214.00) | (320.61) | (622.69) | (690.51) | 0.00 | 0.00 | 0.00 | +135.7 pt | ||||||
| ROE | — | 43.36 | 63.90 | (24.58) | (11.90) | (26.33) | (37.28) | (44.49) | (61.87) | (111.23) | (195.22) | (154.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 44 | 69 | 90 | 87 | 99 | 82 | 43 | 40 | — | (1.4%) | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.09 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Mar 2020 · fundamentals updated 25 Oct 2026
NextCure, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RNAZ TransCode Therapeutics Inc. | $25.6M | — (loss-making) | — | — | n/m | −28.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AARD Aardvark Therapeutics, Inc. | $24.3M | — (loss-making) | — | — | n/m | −77.14% (below 0%: shrinking) | — | 0.00% | Compare |
| CVM Cel-Sci Corporation | $24.1M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $23.5M | — (loss-making) | — (loss-making) | −5.30% (below 0%: shrinking) | n/m | −10.91% (below 0%: shrinking) | 56.79% | (78.00%) | Compare |
| NXTC NextCure, Inc. | $23.4M | — (loss-making) | — (loss-making) | +1,549.08% (above 0%: growing) | n/m | +57.23% (above 0%: growing) | 0.00% | 0.00% | |
| EVAX Evaxion A/S - Sponsored ADR | $23.0M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IGC IGC Pharma, Inc. | $22.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −45.33% (below 0%: shrinking) | 18.60% | (588.72%) | Compare |
| CRVO CervoMed Inc. | $21.9M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FLNA Cassava Sciences, Inc. | $21.8M | — (loss-making) | — | +1,328.04% (above 0%: growing) | n/m | +21.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $23.3M | — | — | −2.65% | — | −19.85% | 18.60% | 0.00% |
Pay and ownership Proxy statement filed 24 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 941.69k | 1.07m | 84.00 |
| 2024 | 1.51m | 1.14m | 55.00 |
| 2023 | 1.04m | 885.07k | 81.00 |
Ownership
Directors and executive officers, together
11.90%
Affinity Asset Advisors, LLC
9.99%
Ikarian Healthcare Master Fund, LP
9.99%
Squadron Master Fund LP
9.99%
Simcere Zaiming, Inc.
9.40%
Sofinnova Venture Partners IX, L.P.
6.20%
Michael Richman
5.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement